Pharmaceutical maker ScinoPharm Taiwan Ltd (台灣神隆) is expected to see its profit increase by 12.7 percent this year on the back of several new drug launches after reporting record earnings for last year, SinoPac Securities Investment Service Co (永豐投顧) forecast.
“We expect that the seven new drugs ScinoPharm Taiwan is about to launch this year will increase its profits since the company can always accurately forecast the timing of its new drug launches and it maintained good relationships with its major global clients, including Teva and Sandoz,” SinoPac Securities said in a report on Thursday.
ScinoPharm opened two local production lines at the end of last year, and the company’s sales of cancer drugs and central nervous system drugs, which account for 89 percent of its revenue, have grown steadily, the report said.
Based on SinoPac’s report, ScinoPharm plans to launch two drugs in Japan and five in the US this year.
SinoPac has predicted that the pharmaceutical maker would see its net profit increase 12.7 percent to NT$1.32 billion (US$44.29 million) this year, or earnings per share of NT$2.03. Revenue is also likely to climb 14.8 percent to NT$5.22 billion this year, it said.
However, SinoPac still retained the rating of ScinoPharm shares as “neutral” because of the high price-earnings ratio of its shares.
SinoPac suggested that investors interested in buying the stock wait until its share price goes down.
The forecasts came after ScinoPharm last week posted NT$1.17 billion in net profit last year, up 21.75 pecent from 2011. Earnings per share were NT$1.8 last year, compared with NT$1.51 the previous year.
Consolidated revenue increased 15.8 pecent to NT$4.57 billion last year from NT$3.95 billion a year ago because of rising production efficiency, higher yield rate of its products and the company’s move to outsource part of its drug production, ScinoPharm said on Wednesday.
The 15.8 percent revenue growth of the company last year was higher than the 1.6 percent growth in 2011 and 2.6 percent growth in 2010, according to the company.
ScinoPharm Taiwan said earlier this year that the Japanese government was encouraging hospitals there to use more generic drugs because they are cheaper, which is a business opportunity for ScinoPharm.
Furthermore, ScinoPharm Taiwan would also benefit from the Chinese government’s attempt to increase the Chinese medicine market by 20 percent a year and the higher standards China has imposed on drug manufacturing factories, SinoPac said.
RECORD BUDGET: TSMC does plan to raise its proposed capital expenditure a lot, and could benefit if Intel outsources more of its production to foundries, analysts said Intel Corp’s earnings conference call on Thursday is expected to clarify the US semiconductor giant’s outsourcing production plans, which would be crucial regarding Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) performance, analysts said. “TSMC stands to benefit if Intel outsources more of its fabrication to foundries,” SinoPac Securities Investment Service Corp (永豐投顧) analysts said in a note on Friday. Yuanta Securities Investment Consulting Co (元大投顧) was more cautious, saying that Intel’s contribution initially would be limited, but its outsourcing plans would still highlight TSMC’s leadership in technology, it added. “Intel will continue to manufacture server or high-end central processing units [CPUs], which have higher
MediaTek Inc (聯發科) yesterday announced it would give incentive bonuses totaling NT$1.7 billion (US$59.7 million) to its employees and those at the firm’s major subsidiaries, after the smartphone chip supplier’s revenue hit US$10 billion last year. This is the biggest incentive bonus the Hsinchu-based handset chip designer has ever distributed in its 23-year history. About 17,000 full-time employees of MediaTek and five of its subsidiaries, including Richtek Technology Corp (立錡科技) and Airoha Technology Corp (絡達科技), would receive a “red envelope” of NT$100,000 each, the company said. “Surpassing US$10 billion is just the beginning. We will continue to [grow] on this basis,” MediaTek
TO SPUR REVENUE: The contract chipmaker expects its profit to grow 15 percent this year, outpacing the foundry industry’s projected advance of about 10 percent Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its projected capital spending for this year by 62 percent, a new high, in an attempt to satisfy customer demand for advanced technologies in the production of central processing units, high-performance-computing (HPC) devices and 5G applications. After investing US$17.24 billion last year, TSMC this year plans to spend US$25 billion to US$28 billion on manufacturing equipment and new facilities, including a fab in the US. About 80 percent of the budget would be allocated for developing advanced technologies including 3, 5 and 7-nanometer technologies, the company said. The larger-than-expected capital spending prompted speculation
Norway’s oil and gas reserves have made it one of the world’s wealthiest countries, but its dreams for deep-sea discovery now center on something different. This time, Oslo is looking for a leading role in mining copper, zinc and other metals found on the seabed and in hot demand in green technologies. The country could license companies for deep-sea mining as early as 2023, the Norwegian Ministry of Petroleum and Energy said, potentially placing it among the first countries to harvest seabed metals for electric vehicle batteries, wind turbines and solar farms. However, that could also place it on the front line of
RSS